Avatrombopag vs. Placebo for CIT in GI Malignancies (NCT05772546)
A Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase 2 Study of Avatrombopag for Persistent Chemotherapy-Induced Thrombocytopenia in Patients With Gastrointestinal Malignancies (ACT-GI)
🩺 Plain-English Summary (8th-Grade Level)
The purpose of this study is to compare the efficacy of two study drugs, Avatrobopag versus placebo, to treat persistent Chemotherapy-Induced Thrombocytopenia (CIT) in patients with gastrointestinal (GI) malignancies receiving cytotoxic chemotherapy. The names of the study drugs involved in this study are: * Avatrombopag (a thrombopoietin receptor agonist) * Matching placebo
Who can join: Review the eligibility criteria below.
Location: University of Miami Sylvester Comprehensive Cancer Center — Miami, Florida
Age range: 18 Years
🧪 Interventions in This Study
📋 "Do I Qualify?" — 1-Minute Self Screener
Instant ChecklistFull eligibility criteria are available on the official NIH protocol. View the criteria ↗
📍 All Participating Trial Locations (4 Sites)
- University of Miami Sylvester Comprehensive Cancer Center — Miami, Florida
- Massachusetts General Hospital Cancer Center — Boston, Massachusetts
- Oregon Health and Science University Hospital — Portland, Oregon
- University of Washington Fred Hutchinson Cancer Center — Seattle, Washington
💰 Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
More studies in Gastrointestinal Cancer
- Advancing Nursing Practices in Hospital Oncology Care — New York, New York
- A Study of Raludotatug Deruxtecan (R-DXd) in People With Gastrointestinal Cancers (MK-5909-005) — New Haven, Connecticut
- Dyadic Sleep Study — Coral Gables, Florida
- EQUITY GI: A Prospective Study to Enhance Quality, Inclusivity, and Trial Participation in Black Patients With Gastrointestinal Cancer. — Cleveland, Ohio
- Intraoperative Imaging of Gastrointestinal Malignancies Using Pafolacianine (CYTALUX™) — Los Angeles, California
Explore by condition: All Gastrointestinal Cancer clinical trials
💡 How to Participate
- Check the checklist above to see if you may qualify.
- Review the official NIH record below to find the coordinating site.
- Ask about the visit schedule, what is covered at no cost, and any travel support.
- Confirm with your own doctor before making a decision.